Detalhe da pesquisa
1.
Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial.
Lancet Oncol
; 22(1): 51-65, 2021 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33285097
2.
Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial.
Lancet
; 394(10212): 1929-1939, 2019 11 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-31590988
3.
Selumetinib Plus Docetaxel Compared With Docetaxel Alone and Progression-Free Survival in Patients With KRAS-Mutant Advanced Non-Small Cell Lung Cancer: The SELECT-1 Randomized Clinical Trial.
JAMA
; 317(18): 1844-1853, 2017 05 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-28492898
4.
Randomized phase II study of pemetrexed/cisplatin with or without axitinib for non-squamous non-small-cell lung cancer.
BMC Cancer
; 14: 290, 2014 Apr 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-24766732
5.
Durvalumab ± Tremelimumab + Platinum-Etoposide in Extensive-Stage Small Cell Lung Cancer (CASPIAN): Outcomes by PD-L1 Expression and Tissue Tumor Mutational Burden.
Clin Cancer Res
; 30(4): 824-835, 2024 02 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-37801329
6.
Afatinib in EGFR TKI-naïve patients with locally advanced or metastatic EGFR mutation-positive non-small cell lung cancer: Interim analysis of a Phase 3b study.
Lung Cancer
; 152: 127-134, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33387727
7.
Afatinib in EGFR TKI-Naïve Patients with Locally Advanced or Metastatic EGFR Mutation-Positive Non-Small Cell Lung Cancer: A Pooled Analysis of Three Phase IIIb Studies.
Front Oncol
; 11: 709877, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-34307179
8.
Patient-reported outcomes with first-line durvalumab plus platinum-etoposide versus platinum-etoposide in extensive-stage small-cell lung cancer (CASPIAN): a randomized, controlled, open-label, phase III study.
Lung Cancer
; 149: 46-52, 2020 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-32961445